Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Tuvusertib in Recurrent IDH Mutant Astrocytoma With ATRX Mutation, a Phase II Prospective Trial.

NCT07417761 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Neurooncología as lead sponsor.

NCT NCT07417761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07417761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Tuvusertib in Recurrent IDH Mutant Astrocytoma With ATRX Mutation, a Phase II Prospective Trial.
Lead sponsor
Grupo Español de Investigación en Neurooncología
Phase
Phase 2
Overall status
Recruiting
Start date
December 19, 2025
Completion date
September 30, 2028
Enrollment
56 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma